Core Insights - The sixth China Stem Cell and Regenerative Medicine Conference has made significant strides in the standardization of biotechnology, marking a milestone for the industry’s high-quality development [3][4]. Group 1: Conference Overview - The conference, themed "Standardization, Integration, Innovation," aimed to create a high-level platform for collaboration and discussion on the standardization of stem cell and regenerative medicine [3]. - Representatives from research institutions, universities, hospitals, enterprises, and regulatory bodies gathered to discuss core topics such as regulatory systems, resource and quality standards, cutting-edge technology applications, and clinical translation [3][4]. Group 2: International Standards and Collaborations - Chinese researchers led the establishment of the International Organoid Working Group under the International Organization for Standardization (ISO), which aims to create international benchmarks for organoid technology [4][5]. - The conference featured the release of two international standards and five group standards developed by the Chinese Society for Cell Biology, emphasizing China's role as a leader in the field [4][5]. Group 3: Technological Advancements and Applications - Organoids, which are miniature tissue models cultivated from stem cells, can accurately simulate the physiological states and disease processes of human organs, holding significant value in biomedical research [5]. - The establishment of a standard system is expected to enhance China's participation in international cooperation and contribute positively to the global scientific innovation ecosystem [5][6]. Group 4: Resource Sharing and Network Expansion - The conference also marked the official announcement of the first sub-library of the National Stem Cell Resource Bank in Chongqing, enhancing the resource network layout [6]. - New members were added to the collaborative platform, enriching the types of resources and technical capabilities available for shared applications [6].

Group 1 - The sixth China Stem Cell and Regenerative Medicine Collaborative Innovation Platform Conference was held in Beijing, focusing on "standardization, integration, and innovation" to build a high-level communication and cooperation platform [1] - The National Stem Cell Resource Bank's first sub-bank was officially announced, enhancing the resource network layout of the National Stem Cell Resource Bank [2] - The "Resource Sharing · Star Plan" was launched, where 20 member units will provide cell and organoid resources for young researchers and startups, promoting high-level collaborative sharing [3] Group 2 - Two international standards and five group standards were released, marking significant progress in international standardization led by China in the field of organoids [5] - The establishment of the International Organoid Standardization Working Group under the International Organization for Standardization (ISO) signifies China's transition from a follower to a leader in international standard setting in life sciences [5]

位于生物岛上的中科天泽生物科技（广州）有限公司总经理助理徐俊颖在接受第一财经采访时表示，新 政策能提高注册申请效率，缩减30%至40%的时间。 记者了解到，广州开发区将重点打造"科技研发在生物岛、成果转化在科学城、生产制造在知识城"的产 业链区域分布。其中，将位于广州城市中央的生物岛扩容升级做强广州生物医药核心引擎，打造成为生 物医药科技创新策源地和产业发展核心高地。 据生物岛管委会党委委员、副主任梅花介绍，近年来，生物岛面向生物经济主战场，精心培育出生物医 药研发、高端医疗器械、干细胞与再生医学、医学检验检测、生物科技配套服务"4+N"主导产业。 目前，岛上已汇聚500多家生物医药企业，其中有阿斯利康、广药、安捷伦、赛默飞、丹纳赫、思拓凡 等世界五百强项目7个，金域、燃石、一品红、百奥泰、文远知行等上市公司总部5家，以及百济神州、 恒瑞、康方、绿叶、正大天晴、粤港澳大湾区高性能医疗器械创新中心等龙头企业。 新政将为生物医药产业提供全流程、全链条扶持 广州开发区将重点打造"科技研发在生物岛、成果转化在科学城、生产制造在知识城"的产业链区域分 布。 7月29日，在广州国际生物岛上，广州开发区科技创新局对《广州开 ...